The objective of this review is to describe the diagnosis of neck vein obstruction and the possible role of chronic persistent Chlamydophila pneumoniae infection in producing the syndrome of chronic cerebrospinal venous obstruction.
Method
The normal patterns of flow in the neck veins are described and guidelines for interpretation of the quantitative duplex ultrasound examination of the extracranial neck veins are developed.
Result
An infective cause of neck vein obstruction is proposed and from a literature search of the role of the obligate intracellular bacterium Chlamydophila pneumoniae in vascular and chronic diseases, a diagnostic protocol for confirming chronic persistent Chlamydophila pneumoniae infection, which includes the quantitative duplex ultrasound examination and specific blood tests are suggested.
Conclusion
Further research to validate this diagnostic protocol is required.
ZamboniPGaleottiRMenegattiEet al.
Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis.J Neurol Neurosurg Psychiatry2009;
80: 392–399.
2.
ThibaultPAttiaJOldmeadowC.A prolonged antibiotic protocol to treat persistent Chlamydophila pneumoniae infection improves the extracranial venous circulation in multiple sclerosis.Phlebology2018;
33: 397–406.
3.
ThibaultPK.Multiple sclerosis: a chronic infective cerebrospinal venulitis?Phlebology2012;
27: 207–218.
4.
SaikkuP.Epidemiology of Chlamydia pneumoniae in atherosclerosis.Am Heart J1999;
138: S500–503.
5.
TobinickEVegaCP.The cerebrospinal venous system: anatomy, physiology, and clinical implications.Med Gen Med2006;
8: 53.
6.
ValduezaJMvon MünsterTHoffmannOet al. Postural dependency of the cerebral venous outflow.Lancet2000;
355: 200–201.
7.
DoeppFSchreiberSJvon MünsterTet al. How does the blood leave the brain? A systematic ultrasound analysis of cerebral venous drainage patterns.Neuroradiology2004;
46: 565–570.
8.
ChambersBChambersJChurilovL.Internal jugular and vertebral vein volume flow in patients with clinically isolated syndrome or mild multiple sclerosis and healthy controls: results from a prospective sonographer-blinded study.Phlebology2014;
29: 528–535.
9.
ThibaultPLewisWNiblettS.Objective duplex ultrasound examination of the extracranial circulation in patients undergoing venoplasty of internal jugular vein stenosis: a pilot study.Phlebology2015;
30: 98–104.
10.
ZamboniPGaleottiRMenegattiEet alChronic cerebrospinal venous insufficiency in patients with multiple sclerosis.J Neurol Neurosurg Psychiatry2009;
80: 392–399.
11.
SchreiberSJLürtzingFGotzeRet al. Extrajugular pathways of human cerebral venous blood drainage assessed by duplex ultrasound.J Appl Physiol2003;
4: 1802–1805.
12.
GeiffersJvan ZandberganGRuppJet al. Phagocytes transmit Chlamydophila pneumonia from the lungs to the vasculature.Eur Respir J2004;
23: 506–510.
13.
ColeWRWitteMHWitteCL.Lymph culture: a new tool for the investigation of human infections.Ann Surg1969;
170: 705–713.
14.
KalayogluMVPerkinsBNByrneGI.Chlamydia pneumoniae-infected monocytes exhibit increased adherence to human aortic endothelial cells.Microbes Infect2001;
3: 963–969.
15.
MolestinaREMillerRDRamirezJAet al. Infection of human endothelial cells with Chlamydia pneumoniae stimulates transendothelial migration of neutrophils and monoctyes.Infect Immun1999;
67: 1323–1330.
16.
KälvegrenHMajeedMBengtssonT.Chlamydia pneumoniae binds to platelets and triggers P-Selectin expression and aggregation: a causal role in cardiovascular disease?Arterioscler Thromb Vasc Biol2003;
23: 1677–1683.
KalayogluMLibbyPByrneGI.Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease.JAMA2002;
288: 274–231.
21.
GraystonJTCampbellLAKuoCCet al. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR.J Infect Dis1990;
161: 618–625.
22.
PaldaniusMBloiguALeinonenMet al. Measurement of Chlamydia pneumoniae-specific immunoglobulin A (IgA) antibodies by the microimmunofluorescent (MIF) method: comparison of seven fluorescein-labelled anti-human IgA conjugates in an in-house MIF test using one commercial MIF and one enzyme immunoassay kit. Clin Diagn Lab Immunol2003;
10: 8–12.
23.
EkmanMRLeinonenMSyrjalaHet al. Evaluation of serological methods in the diagnosis of Chlamydia pneumoniae pneumonia during an epidemic in Finland.Eur J Clin Microbiol Infect Dis1993;
12: 756–760.
24.
SchumacherALerkerodBSeljeflotIet al. Chlamydia pneumoniae serology: importance of methodology in patients with coronary heart disease and healthy individuals.J Clin Microbiol2001;
39: 1859–1864.
25.
Grayston JT.
Infections caused by Chlamydia pneumoniae strain TWAR. Clin Infect Dis1992;
15: 757–761.
26.
GraystonJT.Background and current knowledge of Chlamydia pneumoniae and atherosclerosis.J Infect Dis2000;
181: 402–410.
27.
SaikkuPLeinonenMTenkanenLet al. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study.Ann Intern Med1992;
116: 273–278.
28.
DowellSPeelingRBomanJet al. Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada).Clin Infect Dis2001;
33: 492–503.
29.
MurrayLJO’ReillyDPJOngGMLet al. Chlamydia pneumoniae antibodies are associated with an atherogenic lipid profile.Heart1999;
81: 239–244.
30.
LaurilaABloiguANäyhäSet al. Chlamydia pneumoniae antibodies and serum lipids in Finnish men: cross sectional study.BMJ1997;
314: 1456–1457.
31.
MarangoniAFiorinoEGilardiFet al. Chlamydia pneumoniae acute liver infection affects hepatic cholesterol and triglyceride metabolism in mice.Atherosclerosis2015;
241: 471–479.
32.
KalayogluMVByrneGI.Induction of macrophage foam cell formation by Chlamydia pneumoniae.J Infect Dis1998;
177: 725–729.
33.
KalayogluMVHoernemanBLaVerdaDet al. Cellular oxidation of low-density lipoprotein by Chlamydiae pneumoniae.J Infect Dis1999;
180: 780–790.
34.
KälvegrenHBylinHLeandersonPet al. Chlamydia pneumoniae induces nitric oxide synthase and lipoxygenase-dependent production of reactive oxygen species in platelets. Effects on oxidation of low density lipoproteins. Thromb Haemost2005;
94: 327–335.
35.
KolABourcierTLichtmanAHet al. Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells and macrophages.J Clin Infest1999;
103: 571–557.
36.
RosenbergerKDembnyPDerkowKet al. Intrathecal heat shock protein 60 mediates neurodegeneration and demyelination in the CNS through a TLR4- and MyD88-dependent pathway.Mol Neurodegener2015;
10: 5.
37.
LehnardtSSchottETrimbuchTet al. A vicious cycle involving release of heat shock protein 60 from injured cells and activation of toll-like receptor 4 mediates neurodegeneration in the CNS.J Neurosci2008;
28: 2320–2331.
38.
PrabhakarSKurienEGuptaRSet al. Heat shock protein immunoreactivity in CSF: correlation with oligoclonal banding and demyelinating disease.Neurology1994;
44: 1644–1618.
39.
HalcoxJPJRoyCTubachFet al. C-reactive protein levels in patients at cardiovascular risk: EURIKA study. BMCCardiovasc Disord2014;
14: 25.
RovainenMViik-KajanderMPalosuoMDet al. Infections, inflammation, and the risk of coronary heart disease.Circulation2000;
101: 252–257.
42.
JohnstonSCMessinaLMBrownerWSet al. C-reactive protein levels and viable Chlamydia pneumoniae in carotid artery atherosclerosis.Stroke2001;
32: 2748–2752.
43.
JohnstonSCZhangHMessinaLMet al.
Chlamydia pneumoniae burden in carotid arteries is associated with upregulation of plaque interleukin-6 and elevated C-reactive protein in serum.Arterioscler Thromb Vasc Biol2005; 25: 2648–2653.
44.
HaubitzMBrunkhorstR. C-reactive protein and chronic Chlamydophila pneumoniae infection – long term predictors for cardiovascular disease and survival in patients on peritoneal dialysis.Nephrol Dial Transplant2001;
16: 809–815.
45.
MosorinMJuvonenJBiancariFet al. Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized double-blind, placebo controlled pilot study.J Vasc Surg2001;
34: 606–610.
46.
JacksonLACampbellLASchmidtRAet al. Specificity of detection of C pneumoniae in cardiovascular atheroma. Evaluation of the innocent bystander hypothesis.Am J Pathol1997;
150: 1785–1790.
47.
AbdulkarimASPetrovicLMKimWRet al. Primary biliary cirrhosis: an infectious disease caused by Chlamydia pneumoniae?J Hepatol2003;
40: 380–384.
48.
Yildiz HWieërs GYombi JCet al. Liver granulomatosis: a case of Chlamydophila pneumoniae infection.Acta Clinica Belgica 2014;70: 50–52.
49.
MarangoniADonatiMCavriniFet al. Chlamydia pneumoniae replicates in Kupffer cells in mouse model of liver infection.World J Gastroenterol2006;
12: 6453–6457.
50.
RichardsonAHawkinsSShadabiFet al. Enhanced laboratory diagnosis of human Chlamydia pneumoniae infection through pattern recognition derived from pathology database analysis. In: ChettyMAhmadSNgomATengSW (eds) Third IAPR international conference on pattern recognition in bioinformatics,
Melbourne, Australia, 2008, pp. 227–234.
51.
SkaarEP.The battle for iron between bacterial pathogens and their vertebrate hosts.PLoS Pathogens2010;
6: e1000949.
52.
Al-YounesHMRudelTBrinkmanVet al. Low iron availability modulates the course of Chlamydophila pneumoniae infection.Cell Microbiol2001;
3: 427–437.
53.
GanzTNemethE.Iron homeostasis in host defence and inflammation.Nat Rev Immunol2015;
15: 500–510.
54.
EdvinssonMFriskPBomanKet al. Chlamydophila pneumoniae changes iron homeostasis in infected tissues.Int J Med Microbiol2008;
298: 635–644.
55.
EdvinssonMTallkvistJNyström-RosanderCet al. Iron homeostasis in tissues is affected during persistent Chlamydia pneumoniae infection in mice.Biomed Res Int2017; 2017: 3642301.
56.
OuelletteSPByrneGI.Chlamydia pneumoniae: prospects and predictions for an emerging pathogen. In: FriedmanHYamamotoYBendinelliM (eds) Chlamydia pneumoniae: infection and disease.
New York:
Kluwer Academic/Plenum Publishers, 2004, pp. 1–9.
